Citi Downgrades Relypsa, Inc. (RLYP) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Cantor Fitzgerald Downgrades Relypsa, Inc. (RLYP) to Hold
July 26, 2016 7:38 AM EDTCantor Fitzgerald downgraded Relypsa, Inc. (NASDAQ: RLYP) from Buy to Hold with a price target of $32.00 (from $41.00).
For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.
Shares of Relypsa, Inc. closed at $31.97 yesterday.
... MoreGalenica to Acquire Relypsa (RLYP) for $32/Share
July 21, 2016 5:42 AM EDTGalenica Group and Relypsa, Inc. (Nasdaq: RLYP) announced that the companies have entered into a definitive agreement under which Galenica will acquire Relypsa. This transaction further strengthens Galenicas Business unit, Vifor Pharma, as the company will gain full global rights to the potassium binder Veltassa (patiromer) for oral suspension and enhance its growing position as a global specialty pharmaceutical company. Under the terms of the merger agreement, Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion. Through this acquisition, Vifor Pharma will gain a fully-integrated commercial organization in the United... More
